Cyteir Therapeutics competitors

Jack Bailey is a Corporate Advisor at Eshelman Institute for Innovation, Chief Executive Officer at G1 Therapeutics Inc, and Vice President at ELI LILLY & CO and is based in Chapel Hill, North Carolina. He has worked as Senior VP:US Account Markets at ELI LILLY & CO, Consultant at GSK, and President:US Pharmaceuticals at GSK. Jack works or has worked as BOARD MEMBER at Joint Commission Resources, BOARD MEMBER at Triangle Global Health Consortium Inc, and BOARD MEMBER at National Pharmaceutical Council Executive Committee. He attended Hobart and William Smith Colleges, University of North Carolina at Chapel Hill, and UNC Kenan-Flagler Business School.

Global leader in the oncology pharmaceutical sector having successfully developed, acquired and launched several multi-billion dollar oncology brands across multiple tumor types and therapeutic approaches. Over 3 decades of experience in US and International pharmaceutical development, product strategy, commercialization and business development; and, has cultivated an extensive network with specialists and companies developing new treatment approaches for patients living with cancer. Recently, founded Proventus Health Solutions, a company specializing in helping oncology biotech companies create greater value by integrating development and commercial considerations into a unified approach. A member of the board of directors for Verastem Oncology (VSTM) and Oncopeptides AB (ONCO).

Experienced Board Member, Inventor and Serial Entrepreneur with a demonstrated history of success in the biotechnology industry. Skilled in Biotechnology, Product Development, Life Sciences and Transactions. Strong business development professional with a Ph.D. focused in Pharmaceutical Sciences from the University of Nottingham. Winner EY Entrepreneur of the Year 2014, NJ Region.

Vuong Trieu has been involved in drug discovery and development for over 20 years and has directly supported seven drug candidates from preclinical to clinical to commercialization. Previously, Vuong Trieu served at Parker Hughes Center as director of Cardiovascular Biology program that evaluated a series of small molecules and biologics against preclinical models of atherosclerosis, dyslipidemia, stroke, ALS, and restenosis. Vuong Trieu has 34 peer-reviewed scientific articles and has 25 issued patents and 62 patent applications.

David Arthur is a Chief Executive Officer at SALARIUS PHARMACEUTICALS, INC. and Board Member at SALARIUS PHARMACEUTICALS, INC. and is based in Wilton, Connecticut. He has worked as Managing Director at Dacon Pharma LLC, Process Improvement Engineer and Production Manager at Milliken & Co, and Business Development RTP N.C. at GSK. David studied at Fuqua School of Business between 1988 and 1990 and NC State University between 1980 and 1984.

Dr. Worland has served as a member of the board of directors since February 2015. Dr. Worland is currently President and Chief Executive Officer and a director of eFFECTOR Therapeutics, Inc., a company focused on new treatments for cancer, where he has served since May 2012. Previously, Dr. Worland was President and Chief Executive Officer and a director of Anadys Pharmaceuticals, Inc., a biopharmaceutical company which discovered and developed treatments for hepatitis C and cancer, from August 2007 until the company’s acquisition by Roche in November 2011. Dr. Worland joined Anadys in 2001 and served in a number of executive roles prior to being named Chief Executive Officer, including President, Pharmaceuticals, and Chief Scientific Officer. Dr. Worland began his healthcare industry career at Agouron Pharmaceuticals, Inc. and remained with the company through its successful commercialization of an HIV protease inhibitor and successive acquisitions by Warner-Lambert and Pfizer. During this period, Dr. Worland held a number of positions, including Vice President, Antiviral Research and Director, Molecular Biology and Biochemistry. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University. Dr. Worland received his B.S. with highest honors in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.

Robert Ross is a Board Member at Obsidian Therapeutics, Board Member at SURFACE ONCOLOGY INC., and Chief Executive Officer at SURFACE ONCOLOGY INC. and is based in Brookline, Massachusetts. He has worked as Chief Medical Officer at SURFACE ONCOLOGY INC.. Robert studied at Columbia University in the City of New York between 1995 and 1999, Teachers College Columbia University, and Harvard University between 2005 and 2007.